In a clinical and therapeutic perspective, monitoring and modulating CD4+ T-cells IL-4 production via the VGVAPG/S-gal receptor may lead to the development of innovative personalized biological treatments in COPD. The gene discussed is IL4; the disease is chronic obstructive pulmonary disease.